Table 1.
Summary of treatments in BALB/c mice.
| Vaccination pathwaya | Treatmentsb | Mice numberc |
|---|---|---|
| Intramuscular | 100 μL PBS | 15 |
| 100 μL (3 × 108 PFU) Ad-UMAS | 15 | |
| Intravenous | 50 μL PBS | 15 |
| 50 μL (3 × 108 PFU) Ad-UMAS | 15 | |
| Subcutaneous | 200 μL PBS | 15 |
| 200 μL (3 × 108 PFU) Ad-UMAS | 15 | |
| Intraoral | 200 μL PBS | 15 |
| 200 μL (3 × 108 PFU) Ad-UMAS | 15 | |
| Intranasal | 20 μL PBS | 15 |
| 20 μL (3 × 108 PFU) Ad-UMAS | 15 |
The mice were randomly divided into intramuscular, intravenous, subcutaneous, intraoral, and intranasal immunization groups (15 mice per group).
For the intramuscular group, the mice were injected 100 μL (3 × 108 PFU) Ad-UMAS vaccine in the quadriceps muscle. For the intravenous group, the mice were injected 50 μL (3 × 108 PFU) Ad-UMAS vaccine in the caudal vein. The subcutaneous and oral groups were each administered 200 μL (3 × 108 PFU) Ad-UMAS vaccine. For the nasal group, each mouse was given a nasal drip of 20 μL (3 × 108 PFU) Ad-UMAS vaccine.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.